Programmable cells that find and heal arthritic joints
Engineered cells as agents of arthritis therapy governed by artificial signaling
This research develops engineered cells that sense joint damage and deliver built-in healing signals for people with osteoarthritis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11193998 on NIH RePORTER |
What this research studies
Researchers are designing living cells that detect signs of cartilage breakdown and switch on therapeutic genes only where joint degeneration is present. The approach uses synthetic biology sensors to limit activity to damaged tissue and reduce unwanted effects elsewhere. Work now combines laboratory and animal testing to refine safety and effectiveness before any human use. If those steps succeed, the goal is to offer a cell-based regenerative option that repairs cartilage and reduces joint inflammation.
Who could benefit from this research
Good fit: Adults with symptomatic, progressive osteoarthritis—especially those with cartilage loss who have not achieved lasting relief from current biologic therapies—would be most likely to qualify for future trials.
Not a fit: People with joint pain from non-osteoarthritis causes, very mild osteoarthritis, or medical conditions that make cell therapies unsafe may not receive benefit from this approach.
Why it matters
Potential benefit: If successful, this could produce treatments that rebuild cartilage, stabilize joints, and reduce the need for surgery in osteoarthritis patients.
How similar studies have performed: Related engineered-cell and regenerative strategies have shown promising results in laboratory and animal models but are not yet proven safe and effective in humans.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Brunger, Jonathan Matthew — Vanderbilt University
- Study coordinator: Brunger, Jonathan Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.